X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SIGA will drive international promotion activities for oral TPOXX, a novel small-molecule drug, approved by the FDA for the treatment of smallpox, while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SIGA Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2024
Details:
Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent antidote.
Lead Product(s): Atropine,Pralidoxime Chloride
Therapeutic Area: Pharmacology/Toxicology Product Name: DuoDote
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ASPR
Deal Size: $9.9 million Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2023
Details:
TPOXX (tecovirimat) receive EMA approval for use in the EU as an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: SIGA Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
Public Health Agency of Canada has contracted Meridian Medical Technologies for the purchase up to approximately $33 million of oral TPOXX® within five years. TPOXX® is an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Public Health Agency of Canada
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
